2025
SJR Q3
JCR Q3 · 1,7
7 matched articles
ESCI
Journal detail
Current Treatment Options in Allergy
- Publisher
- Springer Nature
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
21963053
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,468
- Quartile Q3
- H-Index 25
- Cites/doc 1,8
- Docs (3y) 79
- Cites (3y) 160
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,7
- 5Y JIF 1,7
- JCI 0,4
WoS indexes
- ESCI
Subject classification
Categories (SJR)
- Immunology and Allergy Q3
- Medicine (miscellaneous) Q3
Areas
- Medicine
WoS categories
- Allergy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q3 | 0,468 | 1,7 | 1,7 | 0,4 | Q3 | 25 |
| 2024 | Q3 | Q3 | 0,51 | 1,7 | 1,3 | 0,43 | Q3 | 23 |
| 2023 | Q3 | Q3 | 0,407 | 1,9 | — | 0,35 | Q3 | 23 |
| 2022 | Q3 | — | 0,306 | 1,1 | — | 0,22 | Q4 | 23 |
| 2021 | Q3 | — | 0,259 | — | — | 0,17 | Q4 | 23 |
| 2020 | — | — | — | — | — | — | — | 23 |
| 2019 | — | — | — | — | — | — | — | 23 |
| 2017 | — | — | — | — | — | — | — | 23 |
| 2016 | — | — | — | — | — | — | — | 23 |
| 2015 | — | — | — | — | — | — | — | 23 |
| 2014 | — | — | — | — | — | — | — | 23 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ALLERGY | ESCI | Q3 | Q3 | 28/40 |
| 2024 | ALLERGY | ESCI | Q3 | Q3 | 27/40 |
| 2023 | ALLERGY | ESCI | Q3 | Q3 | 25/39 |
| 2022 | ALLERGY | ESCI | — | Q4 | — |
| 2021 | ALLERGY | ESCI | — | Q4 | — |